Background
Nonadherence to antipsychotic medication is one of the major challenges for clinicians treating patients with schizophrenia, 1 and on the order of exercise or weight reduction with regard to trouble in achieving adherence adequate enough to advance beneficial effects. 2 The prevalence of medication nonadherence in schizophrenia is consistent with that of other chronic illnesses (eg, hypertension, asthma). 3 In a review of 39 studies published between 1981 and 2002, Lacro et al noted medication nonadherence rates ranging from 4% to 72% (median, 40%) among patients with schizophrenia, depending on how adherence was defined and measured, the patient population studied (eg, stable vs recently hospitalized outpatients), and the duration and type of evaluation (eg, retrospective, cross-sectional, observational). 4 The 3-year prospective, At the baseline of the W-SOHO study, which recruited 17,384 schizophrenia patients from 37 countries (regions: East Asia, n = 1,223; Europe, n = 12,254; Latin America, n = 2,566; North Africa/Middle East, n = 1,341), 15% of investigators cited incomplete medication adherence as the reason for initiating or changing medication at study entry (range, 10% in East Asia to 21% in Latin America). 5 In the sentinel CATIE trial of patients with chronic schizophrenia, the majority discontinued their assigned antipsychotic agent (a surrogate measure of nonadherence): In Phase I of the study, 74% of 1,460 patients discontinued before completing the 18 months of assigned treatment with an antipsychotic agent. 6 In Phase II of CATIE, 69% of 90 patients (efficacy pathway) and 74% of 333 patients (tolerability pathway) discontinued treatment before completion of the study; median treatment duration was 4 and 5 months in the respective pathways. 7, 8 Taken together, these findings underscore how challenging it is for schizophrenia patients to remain on antipsychotic treatment over a sustained period of time.
The implications of nonadherence for schizophrenia management are far-reaching. 9 Partial/nonadherence to medication has a major impact on the course of illness and treatment outcomes, resulting in persistence of symptoms, approximately fivefold increased risk of relapse (as compared with patients who continue taking their medication), occupational and social dysfunction, increased rate and duration of hospitalization, and increased risk of attempted suicide. [10] [11] [12] [13] In addition, relapse begets relapse, with illness becoming resistant to treatment and previous gains increasingly more difficult to achieve. 14, 15 Nonadherence to medication also impacts cost of care, increasing outpatient service costs for schizophrenia by almost threefold. 16 The Spanish Adherencia Terapéutica en la Esquizofrenia (ADHES) program (translated as: therapeutic adherence in schizophrenia) commenced in 2003, aimed at raising awareness of the problem of partial/nonadherence to medication in the treatment of mental illness. As a component of the ADHES program, a survey was developed and first conducted in Spain, 17 and then in the whole of Europe, the Middle East, and Africa (EMEA), 18 appraising psychiatrists' opinions about the scope and causes of partial or nonadherence to antipsychotic agents among their schizophrenia patients. Using the ADHES survey, the objectives of the study reported here were to determine perceptions of Asia-Pacific (APAC) psychiatrists regarding antipsychotic medication adherence levels among their schizophrenia patients, reasons for their patients' partial/nonadherence, and their preferred methods of assessing adherence.
Methods
The ADHES survey has been described in detail elsewhere. 17 In brief, the ADHES survey consists of 20 questions relating to the demographic characteristics and practice settings of participating psychiatrists and to their perceptions of different factors that affect schizophrenia patients' partial/ nonadherence to antipsychotic medication. The original survey was translated from Spanish to English and then from English into local languages; the survey was then checked for accuracy by native speakers and by back-translation to English before being administered in APAC.
Surveys were handed out at a national conference in India (January 2012) at which the majority of Indian psychiatrists were in attendance. In all other APAC countries, extensive lists of psychiatrists by country were used to disseminate the survey widely during January-April 2012, either by mail (Australia) or via Janssen-Cilag representatives. Psychiatrists received the ADHES survey in a package that also contained a prepaid envelope and a letter explaining the objectives of the survey.
Data collection and analysis
Respondents completed the survey under anonymity; patientspecific information was not collected. No effort was made to follow-up with nonresponding survey recipients. A research agency (Millward Brown, Warwick, UK) summarized survey response data descriptively. Statistical testing was not performed.
In recording their responses, psychiatrists indicated the adherence status of the schizophrenia patients they had seen in the preceding month, by estimating the percentage of patients in each of the following categories: adherent (took $90% of prescribed doses), partially adherent (took $30 to ,90% of prescribed doses), or nonadherent (took ,30% of prescribed doses). 18 The arithmetic mean of the values entered for each of the above categories (ie, percentages of patients who were adherent, partially adherent, or nonadherent to treatment) was calculated based on all respondents who answered the question.
Regarding patients' views and behaviors contributing to partial or nonadherence, psychiatrists were instructed to estimate some responses based on the percentage of patients falling into each of three groupings (ie, ,20%, 20%-50%, and .50% of patients). The mean percent of patients was predefined as: ,20% of patients, mean score value = 10%; between 20% and 50% of patients, mean score value = 35%; and, .50% of patients, mean score value = 75%.
For all questions except those assessing adherence (as noted above), the raw data were converted to percentages that were based on all respondents who were asked the question. If there was no response to the question then that respondent was included in the base, but defaulted into the 'not answered' category. The data were not weighted.
Results
The ADHES survey was distributed to 19,370 psychiatrists across 13 countries in the APAC region. A total of 4,661 (24%) psychiatrists completed the survey. The highest number of respondents practiced in the People's Republic of China and India. The countries in which respondents were in practice (and number of respondents, in decreasing order) were: People's Republic of China (1,854), India (17), and Korea (12) . The respondents were 60% male; 15% aged #30 years, 60% aged 31-50 years, 16% aged 51-60 years, and 7% aged $61 years (2% data missing); and, 76% in clinical (vs academic) practice (Table 1) . Over half (58%) treat their patients, at least in part, in an inpatient setting.
APAC psychiatrists estimated that 56% of patients with schizophrenia are partially or nonadherent with their antipsychotic medication ( Figure 1 Figure 3 ). The majority of psychiatrists assess adherence almost exclusively by asking their patients (81%) or a close informant (86%), versus using objective measures (Figure 4 ), which are used most often in Thailand (75% count pills), Hong Kong, Taiwan, Australia (drug plasma levels measured in 73%, 69%, and 65%, respectively), and the People's Republic of China (63% use logbook and 18% use adherence scale).
Psychiatrists reported that 42% of their patients, on average, need reminding by family members/carers to take their medication as prescribed (range, 36%-37% in Singapore and India to 55%-58% in Taiwan, Indonesia, Thailand, and Hong Kong). Fewer of their patients (36%; range, 30%-31% in Singapore and India, to 48%-59% in Malaysia and Korea) rely on a nurse, psychiatrist, or professional carer to do so.
The strategies considered to manage nonadherence reflect a change or simplification in the current treatment regimen. 
Discussion
The ADHES schizophrenia survey was conducted in APAC to gain insights into the perceptions of psychiatrists in the region regarding the scope and causes of antipsychotic medication nonadherence among their schizophrenia patients as well as the methods of assessing adherence, and preferred strategies to improve adherence. By using a survey administered in the EMEA previously, similarities and differences not only among APAC countries, but also between APAC and EMEA can be identified, thereby promoting a crosscultural understanding of antipsychotic nonadherence in schizophrenia.
We report on a large study sample of 4,661 psychiatrists practicing in 13 countries within the APAC region. The ADHES response rate of 24% in the APAC was twofold higher than that in the EMEA (12%). 18 Although eight of the APAC countries had fewer than 100 respondents each, they were generally well represented in the survey, as reflected by the proportion that respondents comprised to the total number of practicing psychiatrists per country ( 20 this represents approximately 7.9 million affected patients. Overall, similar levels of adherence were reported by psychiatrists across APAC and EMEA, where 53% of patients were reported partially or nonadherent. 18 Within APAC, the lowest rate of nonadherence was reported in Vietnam (30%), which may not be representative of the other countries. Most Vietnamese survey respondents (88%) reported following and treating schizophrenia patients in a hospital, where they can achieve good adherence. Their view on adherence among other patients is limited by the fact that these patients are managed by local mental health care centers, therefore the original treating physicians are not able to monitor and follow-up on their patient's treatment. APAC psychiatrists cited a lack of insight as the main reason for patient partial/nonadherence, a perspective similarly held by EMEA psychiatrists. To the extent that lack of insight is static, trait-like, and unmodifiable by patient education, it follows that cooperation may need to be bypassed, for instance with long-acting injectable antipsychotics. Cognitive impairment was a more common reason for nonadherence in APAC than reported in EMEA. In the opinion of ADHES survey respondents, a minority of schizophrenia patients in APAC (32%) and EMEA (32% 21 ) relate clinical deterioration to antipsychotic nonadherence.
APAC psychiatrists noted that approximately a third of their patients need help from caregivers (family member or professional), placing a burden on them to help patients adhere to their treatment plan. The perceived caregiver burden 
1169
adherence to antipsychotic medication among schizophrenia patients in APAC was lower than that reported in the EMEA 18 ), due in large part to low rates of caregiver burden reported by respondents from India. In APAC countries, more so than in EMEA and other developed regions, schizophrenia patients tend to live with and are supported by an extended family system (rather than in residential facilities), due not only to cultural influences, but also the relative lack of a social welfare system for such patients. 22 Our observations confirm those of others who implicate patients' lack of insight as the most important among factors associated with poor medication adherence in schizophrenia patients. 4, 13 Forming the basis for 2009 Consensus Practice Guidelines 13 for assessing and improving adherence, 41 leading experts in schizophrenia management completed a survey in which they answered questions about the definition and extent of nonadherence, risk factors and assessment methods for nonadherence, and interventions for specific nonadherence problems. The experts ranked the following factors (in descending order of importance) as potential contributors to adherence problems in schizophrenia: poor insight into having an illness; distress associated with persistent side effects (or fear of potential side effects); lack of/partial efficacy with continued symptoms; belief that medications are no longer needed; ongoing substance use problems; cognitive deficits; lack of social support to help with medication-taking; practical problems (eg, transportation, financial); difficulty building therapeutic alliance (with health care providers, caregivers); lack of daily routines; complexity of treatment regimen; significant others ambivalent/opposed to medication; stigma associated with mental illness and medication; and, negative attitudes towards medications in general.
Compared with their EMEA counterparts (76%), APAC psychiatrists assess adherence levels less frequently, with 55% doing so regularly or during every visit. The lowest adherence assessment frequency was reported in the People's Republic of China (51%) and India (42%). Furthermore, APAC psychiatrists reported assessing medication adherence with objective measures less often than EMEA psychiatrists who had previously responded to the ADHES survey. 18 Basing adherence on patient interview can be especially unreliable in countries where patients have negative beliefs about psychiatric conditions or embarrassment about taking antipsychotic medication (Figure 2) .
One out of every three APAC psychiatrists favor switching to or adding a long-acting antipsychotic as their preferred treatment option for addressing adherence problems, compared to three out of every five (62%) EMEA survey respondents. 18 Treatment of schizophrenia patients with a long-acting injectable antipsychotic (vs oral) agent has been shown to decrease relapse and hospitalization rates in many, but not all, studies. 23, 24 The preference of Australian psychiatrists for a long-acting agent (40%), as well as their responses to other questions (eg, higher perceived adherence level, undesirable side effects as a key driver for nonadherence) indicates that they are more aligned with psychiatrists in the EMEA than other APAC countries. This may be a reflection of similarities in its health care system, earlier introduction of long-acting antipsychotic agents, and community-based treatment programs.
Our findings on the prevalence of antipsychotic nonadherence are limited by the fact that its assessment by physicians' clinical judgment oftentimes results in underestimated rates, as compared with an objective tool. 25 A single method for identifying survey respondents was not utilized: some received the survey by mail and others either during a conference or from a representative of the survey's sponsor. Thus, a social desirability bias cannot be ruled out. Furthermore, it is unknown whether the survey sample is representative of all psychiatrists in APAC and whether their responses to the ADHES reflect those of the broad population of their colleagues in the region. Nevertheless, comparisons among APAC countries or between APAC and EMEA on the same survey items remain of interest.
In summary, the substantial prevalence of partial/ nonadherence to antipsychotic medication in APAC, as reported by psychiatrists practicing in the region, demonstrates that more proactive management of patients with schizophrenia is needed to improve adherence and thereby treatment outcomes. To further our findings, future trials could examine other factors affecting adherence (eg, cognitive impairment, disease severity, motivational deficits, stigma, environmental stressors, lack of social support, substance abuse, cultural and religious beliefs, treatmentrelated side effects, poor therapeutic alliance, access to treatment, cost of medication) and other measures of adherence (eg, prolactin). We also propose longitudinal, multi-country study of patients' beliefs, as compared to those of their health care providers.
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